McKesson raised its fiscal 2027 adjusted EPS guidance to $46.40 and completed the $2.25 billion acquisition of Precision Medicine Group. Integration in oncology and specialty services will be a focus for future earnings performance.
In connection with its latest results and guidance, McKesson raised fiscal 2027 adjusted EPS guidance from its previous forecast, pointing to expected earnings growth. The company is also expanding its higher-value platforms and strengthening execution in oncology-related businesses, including RxTS and the US Oncology Network.
The main focus this time is McKesson's completion of the $2.25 billion acquisition of Precision Medicine Group. The deal is expected to advance the integration of specialty pharmaceutical distribution and oncology businesses and expand the company's embedded ecosystem.
The business plan through 2029 assumes revenue of approximately $499.7 billion and earnings of approximately $6.4 billion, based on an annual growth rate of approximately 6.7%. These projections are said to depend on improvements in financial metrics and progress in new integrations.
Factors that could constrain profitability, including costs, policy risks and rising cybersecurity expenses, have also been identified. Market valuation includes fair value estimates and other perspectives, while future execution risk remains a focus for investors.